Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists
Vital information for discovering and optimizing new drugs
"Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors."
-Paul S. Anderson, PhD
This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key concepts are presented with an emphasis on clinical relevance and practical applications.
Targeted to medicinal chemists and pharmacologists, Evaluation of Enzyme Inhibitors in Drug Discovery focuses on the questions that they need to address:
* What opportunities for inhibitor interactions with enzyme targets arise from consideration of the catalytic reaction mechanism?
* How are inhibitors evaluated for potency, selectivity, and mode of action?
* What are the advantages and disadvantages of specific inhibition modalities with respect to efficacy in vivo?
* What information do medicinal chemists and pharmacologists need from their biochemistry and enzymology colleagues to effectively pursue lead optimization?
Beginning with a discussion of the advantages of enzymes as targets for drug discovery, the publication then explores the reaction mechanisms of enzyme catalysis and the types of interactions that can occur between enzymes and inhibitory molecules that lend themselves to therapeutic use. Next are discussions of mechanistic issues that must be considered when designing enzyme assays for compound library screening and for lead optimization efforts. Finally, the publication delves into special forms of inhibition that are commonly encountered in drug discovery efforts, but can be easily overlooked or misinterpreted.
This publication is designed to provide students with a solid foundation in enzymology and its role in drug discovery. Medicinal chemists and pharmacologists can refer to individual chapters as specific issues arise during the course of their ongoing drug discovery efforts.
What people are saying - Write a review
We haven't found any reviews in the usual places.
1 Why Enzymes as Drug Targets?
2 Enzyme Reaction Mechanisms
3 Reversible Modes of Inhibitor Interactions with Enzymes
4 Assay Considerations for Compound Library Screening
5 Lead Optimization and StructureActivity Relationships for Reversible Inhibitors
6 Slow Binding Inhibitors
7 Tight Binding Inhibitors
Other editions - View all
Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal ...
Robert A. Copeland
No preview available - 2013
active site active-site activity assays aspartyl protease binary complex binding pocket Biochem bisubstrate bond captopril catalysis catalytic cell cellular Chapter Chem chemical clinical competitive inhibitors compound concentration of inhibitor conformational Copeland covalent COX2 deﬁned described determine dissociation constant drug discovery dutasteride effects enalaprilate encounter complex enzymatic reaction enzyme active enzyme assay enzyme concentration enzyme inhibitors enzyme molecule Equation equilibrium example ﬁnal ﬁrst ﬁt ﬁtting ﬁxed formation free energy free enzyme function Hence Hill coefﬁcient ICSO values illustrated in Figure inﬂuence inhibition modality inhibitor binding inhibitor concentration inhibitor molecules initial velocity interactions kinetic kobs ligand linear measure mechanism-based inactivators medicinal chemists methods methotrexate microstate modiﬁcation noncompetitive noncompetitive inhibitors optimization peptide potency progress curve protein rate constant reaction mechanism reaction pathway reﬂect residues scissile screening signiﬁcant signiﬁcantly slow binding inhibitor species speciﬁc substrate substrate concentration sulbactam target enzyme tight binding inhibitors tion titration y-intercept